Wednesday, October 21, 2009

The latest on Ampligen

 
"Hemispherx has spent more than $500 million and more than three decades developing the drug."


"Data for final FDA reports are presently undergoing internal auditing at Lovelace and Hemispherx with a projected completion of the final report for late 2009 to early 2010," the company stated in the filing.

No comments: